[{"id":"7bf97edf-e25d-4101-b19d-5329b59d36b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT07204340","created_at":"2025-10-04T08:02:21.190Z","updated_at":"2025-10-04T08:02:21.190Z","phase":"Phase 1","brief_title":"TLN-372 in Advanced KRAS Mutant Solid Tumors","source_id_and_acronym":"NCT07204340","lead_sponsor":"Treeline Biosciences, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 10/09/2025","start_date":" 10/09/2025","primary_txt":" Primary completion: 12/03/2031","primary_completion_date":" 12/03/2031","study_txt":" Completion: 04/01/2032","study_completion_date":" 04/01/2032","last_update_posted":"2025-10-02"},{"id":"c6f24729-d5a7-4244-ad7f-a2cffb7113b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06917079","created_at":"2025-06-07T14:12:37.863Z","updated_at":"2025-06-07T14:12:37.863Z","phase":"Phase 1","brief_title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","source_id_and_acronym":"NCT06917079","lead_sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 287","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-06-06"},{"id":"06993330-e561-4aa2-88d3-c1150ed45ffe","acronym":"","url":"https://clinicaltrials.gov/study/NCT06973564","created_at":"2025-09-07T01:36:33.961Z","updated_at":"2025-09-07T01:36:33.961Z","phase":"Phase 1/2","brief_title":"JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","source_id_and_acronym":"NCT06973564","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 294","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-05-15"},{"id":"e09d9876-48d1-4f6f-9144-1708bb1d0126","acronym":"","url":"https://clinicaltrials.gov/study/NCT06959615","created_at":"2025-09-07T01:30:17.784Z","updated_at":"2025-09-07T01:30:17.784Z","phase":"Phase 1/2","brief_title":"A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration","source_id_and_acronym":"NCT06959615","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 334","initiation":"Initiation: 11/22/2024","start_date":" 11/22/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 08/31/2027","study_completion_date":" 08/31/2027","last_update_posted":"2025-05-06"},{"id":"115521ac-3342-4b27-91a4-3ca392e088b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06447662","created_at":"2024-06-08T04:08:39.171Z","updated_at":"2025-02-25T16:55:59.090Z","phase":"Phase 1","brief_title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","source_id_and_acronym":"NCT06447662","lead_sponsor":"Pfizer","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 06/27/2024","start_date":" 06/27/2024","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/29/2028","study_completion_date":" 07/29/2028","last_update_posted":"2025-02-04"},{"id":"a739f9bd-9e38-4add-a12a-eef9a483a2ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT06607185","created_at":"2025-02-25T17:53:34.609Z","updated_at":"2025-02-25T17:53:34.609Z","phase":"Phase 1","brief_title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","source_id_and_acronym":"NCT06607185","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 10/21/2024","start_date":" 10/21/2024","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2025-01-28"},{"id":"78c12704-ab35-4338-aeed-4cc6fbe8e7c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04111458","created_at":"2021-01-18T20:06:09.981Z","updated_at":"2024-07-02T16:35:09.407Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)","source_id_and_acronym":"NCT04111458","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • BI 1701963"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 10/28/2019","start_date":" 10/28/2019","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-04-16"},{"id":"c588db17-efc8-49b9-af67-a28b72dc4313","acronym":"","url":"https://clinicaltrials.gov/study/NCT06096974","created_at":"2023-10-24T15:13:42.150Z","updated_at":"2024-07-02T16:35:31.995Z","phase":"Phase 1","brief_title":"Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS","source_id_and_acronym":"NCT06096974","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • HRAS mutation","tags":["PD-L1 • KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-17231"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-10-24"},{"id":"77602bae-c8cf-42ee-afb1-9b4462427822","acronym":"","url":"https://clinicaltrials.gov/study/NCT06078800","created_at":"2023-10-12T22:13:54.839Z","updated_at":"2024-07-02T16:35:33.764Z","phase":"Phase 1","brief_title":"A Study of YL-17231 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06078800","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • MSI","pipe":" | ","alterations":" MSI-H/dMMR • KRAS wild-type • RAS wild-type","tags":["PD-L1 • KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-17231"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-12"}]